Clinical trials
Metastatic Oral Cavity Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic oral cavity squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07667400RecruitingPhase 1/Phase 2
Docetaxel plus SX-682 for advanced head and neck or prostate cancer
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Bethesda, MarylandAges 18–120 - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT02290145RecruitingPhase 2
Study of Cyclin D1–targeted chemotherapy before oral cancer surgery
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT07814287RecruitingPhase 2
New drug combo for advanced EGFR-positive head and neck cancer
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Guangzhou, GuangdongAges 18–70 - NCT07807163RecruitingPhase 2
Study of ficerafusp alfa with pembrolizumab for head and neck cancer
This study tests a new drug called ficerafusp alfa combined with pembrolizumab (an immunotherapy) in people with head and neck cancer that has returned or spread. The drug targets a protein that may help the immune system fight the cancer. The study is comparing two different schedules of giving the drug to see which is better.
Fort Myers, FloridaAges 18 years+ - NCT07791745RecruitingPhase 2/Phase 3
Comparing treatments for advanced head and neck cancer
This trial tests a new combination of treatments for head and neck cancer that has returned or spread and can't be cured with local therapy. It compares a standard chemotherapy with or without an additional drug to see which is more effective and safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07717307Recruiting
Comparing two neck surgeries for oral cancer spread
This trial tests whether a smaller neck surgery works as well as a larger one for people with oral cancer that has spread to one lymph node. The goal is to see if less extensive surgery can reduce side effects while still controlling the cancer.
Kolhāpur, MaharashtraAges 21–75 - NCT05286619RecruitingPhase 2
Pembrolizumab with chemotherapy for recurrent head and neck cancer
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Kuala LumpurAges 18 years+ - NCT06380686Recruiting
Head and neck cancer research platform
This trial is collecting information and blood samples from people with head and neck cancer that cannot be cured. It aims to learn more about the cancer and find better ways to treat it.
EssenAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07546383Recruiting
New Immunotherapy Combination for Advanced Head and Neck Cancer
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
Haikou, HainanAges 18–75 - NCT07545967RecruitingPhase 1
Re-radiation and Chidamide for Recurrent Head and Neck Cancer
This trial tests combining re-radiation (radiation therapy given a second time) with a drug called chidamide to treat head and neck cancer that has come back after previous radiation. The goal is to see if this combination can help patients whose cancer cannot be removed by surgery or who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT07529873RecruitingPhase 2
Study of two drugs for advanced head and neck cancer
This trial tests a combination of two medications, ficerafusp alfa and nivolumab, for people with head and neck cancer that has progressed after platinum-based treatment. The goal is to see if this combination can help control the cancer.
VillejuifAges 18–75 - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06489197RecruitingPhase 2
AK112 plus chemo for advanced esophageal cancer
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07465276RecruitingPhase 2
Two immunotherapies before surgery for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07419464RecruitingPhase 2
Testing 5-FU for head and neck cancer that has returned
This trial tests the drug 5-fluorouracil (5-FU) in people with head and neck cancer that has come back or spread. It aims to see if 5-FU can help when other treatments have stopped working.
St Louis, MissouriAges 18 years+ - NCT06470217RecruitingPhase 2
Study of tirilizumab plus chemo for advanced oral cancer
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT07214987RecruitingPhase 2
PDT with immunotherapy and chemo for head and neck cancer
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Boston, MassachusettsAges 18 years+
Hear when a new Metastatic Oral Cavity Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic Oral Cavity Squamous Cell Carcinoma trials by city
Studies with a site in or near these metro areas.
Metastatic Oral Cavity Squamous Cell Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic oral cavity squamous cell carcinoma?
- Yes. Clin2 currently lists 90 recruiting metastatic oral cavity squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic oral cavity squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic oral cavity squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Oral Cavity Squamous Cell Carcinoma
- Recurrent Oral Cavity Squamous Cell Carcinoma
- Locally Recurrent Oral Cavity Squamous Cell Carcinoma
- Oral Squamous Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.